Kyverna Therapeutics reported positive registrational trial results for miv-cel in stiff person syndrome, reinforcing the company’s plan to pursue an FDA submission in mid-year. The company framed the therapy as potentially the first approved CAR-T approach for an autoimmune indication, targeting B cells to reset immune activity. Coverage highlighted that the data set is intended to support regulatory review and that Kyverna aims to convert the efficacy and mobility improvements into a first-of-its-kind approval pathway in autoimmune disease. The company also positioned its CAR-T as a one-time, personalized treatment rather than a long-term chronic regimen. The update adds momentum to the wider CAR-T-for-autoimmunity race, as sponsors try to translate success from hematologic settings into solid evidence for neurologic autoimmune disorders.